Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9341535 | 0.94 | TAAR1 (0.45) | TAAR1HTR2AGPR52CA12CA1 | |
| SCHEMBL9671868 | 0.87 | HIF1A (0.37) | GPR52CA2FFAR1 | |
| SCHEMBL20271906 | 0.87 | GPR52 (0.50) | GPR52PDPK1POLBCTDSP1 | |
| SCHEMBL13801239 | 0.86 | TAAR1 (0.46) | TAAR1HTR2AGPR52CA12CA1 | |
| SCHEMBL28464172 | 0.85 | TAAR1 (0.45) | TAAR1HTR2AGPR52CA12CA1 | |
| SCHEMBL4198535 | 0.83 | TAAR1 (0.43) | TAAR1HTR2AGPR52PLCG1 | |
| SCHEMBL10012084 | 0.80 | HRH3 (0.41) | GPR52FFAR1 | |
| SCHEMBL27963834 | 0.80 | CYP2A6 (0.42) | GPR52PDPK1CYP2A6 | |
| SCHEMBL26988123 | 0.80 | MAOB (0.41) | TAAR1HTR2AGPR52 | |
| SCHEMBL9805398 | 0.79 | RAB9A (0.51) | TAAR1HTR2AGPR52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114956932-B | Synthesis method of polysubstituted chiral tetrahydroquinoline compound | 东北大学秦皇岛分校 | 2023-11-10 | — | — | CN | claimed |
| CN-114956932-A | Synthesis method of polysubstituted chiral tetrahydroquinoline compound | 东北大学秦皇岛分校 | 2022-08-30 | — | — | CN | claimed |
| US-20250382269-A1 | METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES | CFD RES CORPORATION (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250382268-A1 | METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES | CFD RES CORPORATION (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250320201-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| CN-112811994-B | Difluoro ether compound with 3-pentenyl end group and synthesis method thereof | 江苏和成新材料有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-114956932-B | Synthesis method of polysubstituted chiral tetrahydroquinoline compound | 东北大学秦皇岛分校 | 2023-11-10 | — | — | CN | disclosed |
| CN-115536511-B | 1, 4-dialdehyde ketone compound, synthesis method and application thereof | 徐州医科大学 | 2023-08-22 | — | — | CN | disclosed |
| US-5968960-A | ANTIISCHEMIC AGENTS AND HYPOTENSIVE AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-10-19 | — | — | US | disclosed |
| US-5804590-A | ADMINISTERING DERIVATIVES OF THIAZOLIDINE; ANTI-DIABETIC AGENTS. | SANKYO COMPANY, LIMITED (JP) | 1998-09-08 | — | — | US | disclosed |
| US-5753681-A | INSULIN SENSITIZERS | SANKYO COMPANY, LIMITED (JP) | 1998-05-19 | — | — | US | disclosed |
| US-5717109-A | CARBOXYCYCLOPROPYL GLYCINE DERIVATIVES; USEFUL FOR TREATMENT OF ACUTE OR CHRONIC NEURODEGENERATIVE CONDITIONS, AND AS ANTIPSYCHOTIC, ANTICONVULSANT, ANALGESIC, ANXIOLYTIC, ANTIDEPRESSANT AND ANTI-EMETIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-02-10 | — | — | US | disclosed |
| EP-0796618-A1 | Treatment and prophylaxis of pancreatitis | SANKYO COMPANY LIMITED (JP) | 1997-09-24 | — | — | EP | disclosed |
| EP-0783888-A1 | Use of troglitazone and related thiazolidinediones in the manufacture of a medicament for the treatment and prophylaxis of osteoporosis | SANKYO COMPANY LIMITED (JP) | 1997-07-16 | — | — | EP | disclosed |
| EP-0391212-B1 | Process for preparing bifunctional Z-stilbene compounds, new bifunctional Z-stilbene compounds and their use for preparing polymers | BAYER AG (DE) | 1994-05-25 | — | — | EP | disclosed |
| US-4486433-A | SLOWING HEART RATE | DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1984-12-04 | — | — | US | disclosed |
| US-4409220-A | Fused-ring amino-pyrazines as bradycardiac agents | DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1983-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250382269-A1 | METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES | CD14, MIF, NOD2 | TAAR1 2151/4885HTR2A 4846/4885GPR52 2846/4885 |
| US-20250320201-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | TAAR1 3429/4885HTR2A 1684/4885GPR52 2683/4885 |
| US-20250382268-A1 | METHODS AND COMPOSITIONS FOR SELECTIVELY INHIBITING PATHOGENIC MICROBES | CD14, MIF, NOD2 | TAAR1 2151/4885HTR2A 4846/4885GPR52 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.